Glofitamab + Chemotherapy for Non-Hodgkin's Lymphoma

Recruiting in Palo Alto (17 mi)

+12 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Hoffmann-La Roche

No Placebo Group

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?This trial is testing a new drug called glofitamab combined with other cancer drugs in patients with a type of lymphoma that hasn't responded to previous treatments. The treatment works by helping the immune system attack cancer cells and using chemotherapy to kill or stop the growth of these cells.

Eligibility Criteria

This trial is for people with a type of cancer called diffuse large B-cell lymphoma that has come back or didn't respond after their first treatment. They must have had therapy before that included an anti-CD20 antibody and anthracycline, be healthy enough to consider more intense treatments like stem cell transplant or CAR-T therapy, and not have certain medical conditions.

Inclusion Criteria

Life expectancy ≥ 12 weeks

I am eligible for intense chemotherapy followed by stem cell or CAR-T therapy.

My cancer is a type of B-cell lymphoma confirmed by lab tests.

+3 more

Exclusion Criteria

I have had a stem cell transplant from a donor.

I am on a stable dose of corticosteroids not exceeding 30 mg/day for at least 4 weeks.

I have or had a brain-related condition like stroke or epilepsy.

+17 more

Participant Groups

Researchers are testing how well Glofitamab works when given with Rituximab plus Ifosfamide, Carboplatin, and Etoposide in patients whose cancer returned or resisted the first line of treatment. The study will look at the drug's effects on the body and its safety.

1Treatment groups

Experimental Treatment

Group I: R/R DLBCLExperimental Treatment7 Interventions

Participants will receive up to 3 21-day cycles of glofitamab, rituximab, ifosfamide, carboplatin, and etoposide (glofit-R-ICE).

Carboplatin is already approved in United States, European Union, Canada for the following indications:

🇺🇸 Approved in United States as Paraplatin for: